Ceruvia Lifesciences Submits FDA Investigational New Drug Ap

Based on a positive pre-IND meeting with the U.S. Food and Drug Administration (FDA), Ceruvia Lifesciences has submitted an Investigation New Drug (IND) application to begin a Phase 2 clinical

Related Keywords

United States , Americans , Ceruvia Lifesciences , Kostenloser Wertpapierhandel , Benjamin Kelmedi , Christopher Pittenger , Carey Turnbull , Prnewswire Ceruvia Lifesciences , Judy Ashworth , School Of Medicine , Yale School Of Medicine , Harvard University School Of Medicine Ceruvia , Yale University School Of Medicine , Drug Administration , Investigation New Drug , Yale School , Principal Investigators , Yale University School , Sheehan Disability , Chief Medical Officer , Harvard University School , Medicine Ceruvia , Ceruvia , Lifesciences , Ubmits , Investigational , Drug , Application , Silocybin , Obsessive , Compulsive , Disorder , Program ,